Humacyte Inc (NASDAQ: HUMA) has experienced a rise in its stock price by 10.60 compared to its previous closing price of 7.55. However, the company has seen a fall of -0.60% in its stock price over the last five trading days. seekingalpha.com reported 2024-07-22 that Humacyte, a bioengineering company, went public through a SPAC merger in 2015, with a market value of $1.1 billion. The company has received FDA’s RMAT designation for three indications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Humacyte’s potential product, Acellular Tissue Engineered Vessel, has shown promise in addressing critical medical needs, with a pending FDA approval decision on August 10th.
Is It Worth Investing in Humacyte Inc (NASDAQ: HUMA) Right Now?
The stock has a 36-month beta value of 1.50. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HUMA is 91.98M, and at present, short sellers hold a 8.97% of that float. On July 23, 2024, the average trading volume of HUMA was 3.09M shares.
HUMA’s Market Performance
HUMA’s stock has seen a -0.60% decrease for the week, with a 59.35% rise in the past month and a 125.68% gain in the past quarter. The volatility ratio for the week is 10.30%, and the volatility levels for the past 30 days are at 10.68% for Humacyte Inc. The simple moving average for the past 20 days is 36.38% for HUMA’s stock, with a 112.84% simple moving average for the past 200 days.
Analysts’ Opinion of HUMA
Many brokerage firms have already submitted their reports for HUMA stocks, with H.C. Wainwright repeating the rating for HUMA by listing it as a “Buy.” The predicted price for HUMA in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on December 11, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see HUMA reach a price target of $3.50, previously predicting the price at $2.75. The rating they have provided for HUMA stocks is “Neutral” according to the report published on August 14th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to HUMA, setting the target price at $6 in the report published on June 22nd of the previous year.
HUMA Trading at 28.71% from the 50-Day Moving Average
After a stumble in the market that brought HUMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.25% of loss for the given period.
Volatility was left at 10.68%, however, over the last 30 days, the volatility rate increased by 10.30%, as shares surge +61.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +85.14% upper at present.
During the last 5 trading sessions, HUMA fell by -0.60%, which changed the moving average for the period of 200-days by +203.64% in comparison to the 20-day moving average, which settled at $6.28. In addition, Humacyte Inc saw 194.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HUMA starting from Dougan Brady W, who sale 271,518 shares at the price of $7.30 back on Jun 12 ’24. After this action, Dougan Brady W now owns 4,559,140 shares of Humacyte Inc, valued at $1,982,081 using the latest closing price.
Niklason Laura E, the President, CEO and Director of Humacyte Inc, sale 271,518 shares at $7.30 during a trade that took place back on Jun 12 ’24, which means that Niklason Laura E is holding 4,559,140 shares at $1,982,081 based on the most recent closing price.
Stock Fundamentals for HUMA
Current profitability levels for the company are sitting at:
- -9.65 for the present operating margin
- 0.21 for the gross margin
The net margin for Humacyte Inc stands at -9.8. The total capital return value is set at -0.71. Equity return is now at value -195.68, with -61.38 for asset returns.
Based on Humacyte Inc (HUMA), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at -4.42. The debt to equity ratio resting at 0.71. The interest coverage ratio of the stock is -33.76.
Currently, EBITDA for the company is -92.33 million with net debt to EBITDA at 1.09. When we switch over and look at the enterprise to sales, we see a ratio of 83.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.37.
Conclusion
To sum up, Humacyte Inc (HUMA) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
